Novel Vaccine Against Colorectal Carcinoma (CRC)

Inventor: Dorothee Herlyn

Tech ID: HD-96002

Description: Wistar researchers are investigating novel approaches for immunotherapy of cancer. For one such approach, a replication deficient adenovirus expressing the CRC associated antigen GA733 2 was constructed for active immunotherapy of CRC patients. In Phase II trials, an immune response to this antigen (induced by administration of a monoclonal antibody to GA733 2 antigen) was effective in preventing recurrence of CRC. Administration of GA733 2 inhibits growth of established CRC cells in mice. Since this effect may be mediated by cytotoxic antibodies, and/or cytolytic and proliferative T lymphocytes, active immunotherapy using the GA733-2 antigen may be more effective than passive immunotherapy.

Key Words: Therapeutic, vaccine, cancer, colorectal cancer

Applications and Advantages: The adenovirus expressing the GA733-2 antigen has potential as a vaccine for CRC patients. A Phase I trial using this technology is planned.

Intellectual Property Status: Wistar can provide the adenovirus vector with the GA733-2 antigen.

Licensing Opportunity: A license to the technology is available for any organization that is interested in developing immunotherapy approaches to CRC.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last updated Aug-02